Amgen Inc. (AMG DU) stock market data APIs
€255.4304
-3.11(-1.2%)
as of October 15, 2025
Try our APIs with
free plan!
Amgen Inc. Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for AMG.DU.
Prev. Close
255.4304
Open
252.3167
High
253.941
Low
253.5689
52 wk Range
226.6171-303.0415
Market Cap
105 182 M
Dividends (Yield)
0.0224
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Amgen Inc. data using free add-ons & libraries
Get Amgen Inc. Fundamental Data
Amgen Inc. Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Amgen Inc. News
New
Amgen (AMGN) Laps the Stock Market: Here's Why
In the latest close session, Amgen (AMGN) was up +1.18% at $297.32. The stock's performance was ahead of the S&P 500's daily gain of 0.4%. Meanwhile, the Dow lost 0.04%, and the Nasdaq, a tech-heavy i...
Amgen (AMGN) Announces Launch of AmgenNow
Amgen Inc. (NASDAQ:AMGN) is one of the Best Wide Moat Stocks to Buy Right Now. The company possesses a wide economic moat, which is backed by its intellectual property and brand reputation. On Octobe...
Why Amgen (AMGN) Could Beat Earnings Estimates Again
If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Amgen (AMGN). Th...
Amgen Repatha Phase 3 Trial Meets Dual Primary Endpoints for Primary Cardiovascular Prevention
Amgen Inc. (NASDAQ:AMGN) is one of the best growth stocks to buy now. On October 2, Amgen announced that its landmark Phase 3 VESALIUS-CV clinical trial met its dual primary endpoints, confirming that...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
